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Soluble Siglec-5 associates 
to PSGL-1 and displays anti-
inflammatory activity
Marion Pepin1, Soraya Mezouar2, Julie Pegon1, Vincent Muczynski1, Frédéric Adam1, 
Elsa P. Bianchini1, Amine Bazaa1, Valerie Proulle1,3, Alain Rupin4, Jerome Paysant5, 
Laurence Panicot-Dubois2, Olivier D. Christophe1, Christophe Dubois2, Peter J. Lenting1 & 
Cécile V. Denis1
Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates 
leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand 
for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble 
Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding 
to PSGL1. Pre-treatment of PSGL1 with sialidase reduced Siglec-5 binding by 79 ± 4%. In confocal 
immune-fluorescence assays, we observed that 50% of Peripheral Blood Mononuclear Cells (PBMCs) 
simultaneously express PSGL1 and Siglec-5. Duolink-proximity ligation analysis demonstrated that 
PSGL1 and Siglec-5 are in close proximity (<40 nm) in 31 ± 4% of PBMCs. In vitro perfusion assays 
revealed that leukocyte-rolling over E- and P-selectin was inhibited by sSiglec-5/Fc or sSiglec-5/C4BP, 
while adhesion onto VCAM1 was unaffected. When applied to healthy mice (0.8 mg/kg), sSiglec-5/C4BP  
significantly reduced the number of rolling leukocytes under basal conditions (10.9 ± 3.7 versus 
23.5 ± 9.3 leukocytes/field/min for sSiglec-5/C4BP-treated and control mice, respectively; p = 0.0093). 
Moreover, leukocyte recruitment was inhibited over a 5-h observation period in an in vivo model of 
TNFalpha-induced inflammation following injection sSiglec-5/C4BP (0.8 mg/kg). Our data identify 
PSGL1 as a ligand for Siglec-5, and soluble Siglec-5 variants appear efficient in blocking PSGL1-
mediated leukocyte rolling and the inflammatory response in general.
The inflammatory response involves a series of events that leads to the recruitment of circulating leukocytes to 
extravascular sites of inflammation1. Many molecular actors have been identified that contribute to this process, 
including the leukocyte-receptor P-selectin glycoprotein ligand-1 (PSGL1)2,3. This single-membrane receptor 
controls rolling of leukocytes on P- and E-selectin-expressing endothelial cells4,5. Indeed, PSGL1-deficiency is 
associated with delayed leukocyte recruitment in an experimental peritonitis model as well as with reduced leu-
kocyte rolling in vivo6. The extracellular domain of PSGL1 is heavily glycosylated5 and the presence of sialic acids 
at the tip of the glycans is crucial to its interaction with P-selectin2.
The presence of the sialylated glycans on PSGL1 also makes this protein a potential ligand for a family of 
sialic-acid recognizing receptors: Siglecs or sialic acid-binding immunoglobulin-like lectins. This family consists of 
14 different members, each of them with its own specificity for the various sialic acid structures and conformations7. 
Two different subfamilies may be distinguished: CD22-related and CD33-related Siglecs. The CD22-related sub-
family is composed of 4 members, including the archetype of this family, Sialoadhesin or Siglec-1, and these 
Siglecs are relatively well conserved between species. The human CD33-related subfamily consists of 10 different 
members, which are poorly conserved between species8. Siglecs are selectively expressed in cells of haematopoie-
tic origin, such as neutrophils, B cells and monocytes, with each Siglec having its own expression pattern8.
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Among the Siglecs, Siglec-5 recognizes a remarkably wide spectrum of sialic acid structures, including 
α 2-3, α 2-6 and α 2-8 linkage conformations, as well as the two most common mammalian sialic acid variants 
(N-acetylneuraminic acid and N-glycolylneuraminic acid)9. The protein structure of Siglec-5 distinguishes 4 
extracellular immunoglobulin-like domains, a single transmembrane domain and a cytoplasmic tail10. It should 
be noted that different splice variants of Siglec-5 can be produced, including a soluble isoform11. In all variants, 
the N-terminal V-set domain contains the sialic acid binding domain11,12. The reported physiological role of 
Siglec-5 seems to be diverse and relates to cell-cell interactions, signaling, recognition of pathogens and endocy-
tosis of ligands7,10,13–17.
Being intrigued by the notion that PSGL-1 and Siglec-5 are both expressed in many leukocytes, combined 
with the presence of sialic acid structures on PSGL1, we investigated the hypothesis that PSGL1 could serve as 
a ligand for Siglec-5. Our data suggest that PSGL1 and Siglec-5 co-localize at the surface of leukocytes, and that 
recombinant PSGL1 binds in a calcium-dependent manner to soluble Siglec-5. Furthermore, soluble Siglec-5 
interferes with the rolling of leukocytes on P-selectin in vitro. Finally, soluble Siglec-5 reduces basal rolling of 
leukocytes in vivo and prevents the recruitment of leukocytes to sites of inflammation.
Results
Soluble Siglec-5 variants. To investigate whether Siglec-5 recognizes the ectodomain of PSGL1, two dif-
ferent Siglec-5 constructs of different cellular origin were used to explore their interaction with soluble PSGL1/Fc 
(sPSGL1/Fc): a commercially available dimeric soluble Siglec-5/Fc fusion protein (sSiglec-5/Fc) and a novel 
heptameric Siglec-5/C4BP fusion protein (sSiglec-5/C4BP; Fig. 1A). This latter protein consists of the Siglec-5 ecto-
domain fused to a 57-amino acid motif that mediates heptamerisation of the C4BP protein (residues 541–597)18. 
Indeed, purified sSiglec-5/C4BP migrates as a single-chain protein of approximately 525 kDa under non-reduced 
conditions. The apparent molecular weight of sSiglec-5/C4BP was estimated to be one-seventh of this value under 
reduced conditions (75 kDa; Fig. 1B), corresponding to the molecular weight of the 487-amino acid polypeptide, 
which harbors 8 sites for N-linked glycosylation.
Interaction between the ectodomains of PSGL1 and Siglec-5. Binding of Siglec-5 variants 
(0–215 nM) to immobilized sPSGL1/Fc (0.25 μ g/well) was first tested in an immunosorbent assay, with bound 
Figure 1. Soluble variants of Siglec-5. Panel A: Domain structures of sSiglec-5/C4BP and sSiglec-5/Fc which 
are used within this study. Panel B: Analysis of purified sSiglec-5/C4BP and sSiglec-5/Fc via SDS-Page and 
Coomassie-staining under non-reduced and reduced conditions.
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Siglec-5 protein being probed using biotin-labeled polyclonal anti-Siglec-5 antibodies. Both sSiglec-5/C4BP and 
sSiglec-5/Fc displayed saturable and dose-dependent binding to immobilized sPSGL1/Fc (Fig. 2A). Half-maximal 
binding was calculated to be 8 ± 1 nM and 49 ± 11 nM for sSiglec-5/C4BP and sSiglec-5/Fc, respectively. Binding 
appeared to be specific, as the interaction of sSiglec-5/C4BP and sSiglec-5/Fc was inhibited in the presence of 
polyclonal anti-Siglec-5 antibodies as well as in the presence of EDTA (Fig. 2B). A similar EDTA-dependence 
was also observed for the binding of P-selectin to immobilized sPSGL1/Fc (Fig. 2B). Binding was further inves-
tigated via BLI-analysis using Octet-QK equipment. Again, sSiglec-5/C4BP displayed a dose-dependent binding 
(Fig. 2C). Specificity was tested by pre-incubating immobilized sPSGL-1/Fc with sialidase prior to incubation 
Figure 2. Interaction between ectodomains of Siglec-5 and PSGL1. Panel A: sSiglec-5/C4BP (closed 
circles) and sSiglec-5/Fc (open circles) were incubated with immobilized sPSGL1/Fc. Plotted is the response 
(OD450nm) versus sSiglec-5 concentration. Data represent mean ± SD of three independent experiments. 
Panel B: sSiglec-5/C4BP (10 μ g/ml), sSiglec-5/Fc (10 μ g/ml) or P-selectin (10 μ g/ml) were pre-incubated with 
EDTA or polyclonal anti-Siglec-5 antibodies prior to the addition of sPSGL1/Fc-coated wells. Plotted is the 
response (OD450) for each of the preparations. P-values were determined in a 1-way ANOVA followed by a 
Tukey’s multiple comparison test. Panel C: Interaction between sPSGL1 and sSiglec-5/C4BP was examined 
using BLI-analysis. sPSGL1/Fc was immobilized onto amine-reactive biosensors and incubated with various 
concentrations of sSiglec-5/C4BP. A representative sensorgram of three independent experiments is plotted, 
showing the response (nm shift) versus time. Panel D: sPSGL1/Fc immobilized onto amine-reactive biosensors 
was incubated in the absence (grey bars) or presence (black bars) of sialidase (0.1 U/ml) before exposure to 
sSiglec-5/C4BP or P-selectin (both 10 μ g/ml). Plotted is the residual response (expressed as percentage of 
response in the absence of sialidase, which was arbitrarily set at 100%) for both sSiglec-5/C4BP and P-selectin. 
Panels E & F: human or murine sPSGL1/Fc (hPSGL1 and mPSGL1) and BSA were immobilized onto amine-
reactive biosensors and incubated with sSiglec-5/C4BP or sSiglec-5/Fc (7.5 μ g/ml). Representative sensorgrams 
of two independent experiments is plotted, showing the response (nm shift) versus time.
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with sSiglec-5/C4BP. Sialidase-treatment of sPSGL1/Fc reduced binding of sSiglec-5/C4BP and P-selectin by 
79 ± 4% and 75 ± 9%, respectively (mean ± SD; n = 3; Fig. 2D). Since in vivo experiments were included in 
this study, we further verified that sSigecl-5/C4BP and sSiglec-5/Fc can interact with murine PSGL1 as well. As 
depicted in Fig. 2E and F, both soluble Siglec-5 variants were similar in binding to human and murine sPSGL1/Fc. 
Taken together, our data indicate that the extracellular region of PSGL1 is able to associate with the extracellular 
region of Siglec-5 in a calcium-ion and sialic acid-dependent manner.
PSGL1 and Siglec-5 are in close proximity at the leukocyte surface. We next explored the possi-
bility that the naturally expressed proteins could also interact at the cell surface. When analyzing the expression 
of PSGL1 and Siglec-5 on freshly isolated PBMCs, we observed that 98 ± 2% (n = 3 PBMC isolations) of the cells 
stained positive for PSGL1 and 52 ± 4% for Siglec-5 (Fig. 3A-B), suggesting that about 50% of the cells express 
both PSGL1 and Siglec-5. We then analyzed co-localization between PSGL1 and Siglec-5 via double immunoflu-
orescence staining. Signals for PSGL1 on Siglec-5-expressing cells indeed displayed some overlap with the signals 
for Siglec-5 (Fig. 3C). To confirm that both proteins truly associate at the cell surface, Duolink-PLA analysis 
was performed. This approach generates red fluorescent spots if proteins are located in a radius of 40 nm. No 
fluorescent spots were formed when either primary antibody was omitted from the assay (Fig. 3D). In contrast, 
distinct red spots were detected in about 30% of the cells when anti-PSGL1 and anti-Siglec-5 antibodies were used 
simultaneously (Fig. 3E). These data show that PSGL1 and Siglec-5 may interact also at the surface of PBMCs, 
indicating that binding is not restricted to the recombinant derivatives of these proteins.
Soluble sSiglec-5/Fc reduces rolling of THP1-cells over E- and P-selectin in vitro. Considering 
that sSiglec-5 variants are able to interact with PSGL1, we explored the possibility that sSiglec-5 could be 
used to interfere with PSGL1 mediated leukocyte rolling. First, we compared rolling of THP1-cells that were 
pre-incubated in the absence or presence of sialidase (0.1 U/ml). The number of THP1-cells rolling over immo-
bilized P-selectin was reduced by > 98% for sialidase-treated THP1-cells compared to non-treated cells (Fig. 4A), 
confirming that P-selectin mediated rolling requires the presence of sialic acids. In a next series of experiments, 
the effect of a single concentration of dimeric sSiglec-5/Fc on the adhesion and/or rolling of THP1-cells on 
various receptors was tested using a microfluidic perfusion system (shear stress: 0.5 dyn/cm2). As a control, 
sSiglec-7/Fc was used, which recognizes a different array of sialic acid conformations compared to sSiglec-5/Fc9. 
In the presence of sSiglec-5/Fc or sSiglec-7/Fc (10 μ g/ml), the number of cells adhering to VCAM1 was unaf-
fected (Fig. 4B). In contrast, rolling on E-selectin or P-selectin-coated coverslips was reduced by 72 ± 14% (n = 3; 
p = 0.0015) and 52 ± 12% (n = 5; p = 0.0084), respectively, in the presence of sSiglec-5/Fc, but not in the pres-
ence of sSiglec-7/Fc (Fig. 4C & D). We subsequently compared sSiglec-5/Fc to anti-PSGL1 antibodies. Both the 
anti-PSGL1-antibodies and sSiglec-5/Fc reduced rolling of THP1-cells over P-selectin in a dose-dependent man-
ner (Fig. 4E). Moreover, both anti-PSGL1-antibodies and sSiglec-5/Fc were equally efficient in reducing rolling of 
THP1-cells at concentrations of 10 and 20 μ g/ml. However, no further decrease in rolling was observed at 50 μ g/ml 
anti-PSGL1-antibodies (50 ± 10% maximal inhibition), whereas rolling was reduced by 81 ± 10% in the presence 
of 50 μ g/ml sSiglec-5/Fc (p = 0.0024 compared to anti-PSGL1 antibodies). Examples of image-sequences depict-
ing rolling of THP1-cells over P-selectin in the absence or presence of sSiglec-5/Fc are shown in Fig. 4F and G. 
Our data suggest that sSiglec-5/Fc is able to specifically interfere with rolling of leukocytes over P-selectin.
Soluble sSiglec-5 variants reduce rolling of PBMCs and PMNs over P-selectin in vitro. To inves-
tigate if soluble Siglec-5 variants also modify rolling of primary leukocytes over P-selectin, perfusion experiments 
using freshly isolated PBMCs and PMNs were performed. Rolling of PBMCs over P-selectin was reduced by 
55 ± 11% (p = 0.0049; n = 3) in the presence of sSiglec-5/Fc, while unaffected by the presence of sSiglec-7/Fc 
(Fig. 5A). As for PMNs, both sSiglec-5/Fc and sSiglec-5/C4BP significantly reduced rolling of these cells over 
P-selectin. Rolling was reduced by 26 ± 16% (p = 0.0020; n = 4) and 41 ± 7% (p = 0.0437; n = 5), respectively 
(Fig. 5B). Thus, sSiglec-5 also interferes with the rolling of PBMCs and PMNs over P-selectin.
sSiglec-5/C4BP reduces basal leukocyte rolling in vivo. To investigate whether sSiglec-5 affects leuko-
cyte rolling in vivo, we first studied the effect of infusion of sSiglec-5/C4BP infusion on basal leukocyte rolling in 
mice. To this end, mice (13–18 g; 3–5 weeks of age) received a single bolus of vehicle or sSiglec-5/C4BP (0.8 mg/kg). 
After preparation of the mesenteric venules (25–35 μ m), leukocyte rolling was monitored for 10 min in two sepa-
rate vessels in 8–9 separate mice. The number of rolling leukocytes under basal conditions was significantly lower 
in sSiglec-5/C4BP-treated mice compared to vehicle-treated mice (10.9 ± 3.7 versus 23.5 ± 9.3 rolling leukocytes/
field/min, respectively; p = 0.0093; Fig. 6A). Moreover, the number of adhering leukocytes (defined as adher-
ing for > 30s) was also reduced significantly in Siglec-5/C4BP-treated mice compared to vehicle treated mice 
(4.1 ± 2.2 versus 8.0 ± 2.4 adhering leukocytes/field, respectively; p = 0.0053; Fig. 6B). These data suggest that 
sSiglec-5/C4BP has the potential to modulate leukocyte rolling and subsequent adhesion in vivo.
sSiglec-5/C4BP prevents leukocyte recruitment in a TNFα-induced model of sterile inflammation. 
We next addressed the question whether sSiglec-5/C4BP could modulate leukocyte recruitment in a sterile 
model of inflammation. To this end, mice were given vehicle or a single bolus of sSiglec-5/C4BP (0.8 mg/kg). 
Subsequently, the cremaster of male mice was prepared and a TNFα -releasing gel was placed on the cremaster 
muscle. Recruitment, rolling and adhesion of Syto59-labeled leukocytes was monitored over a 5-h period using 
intravital spinning-disk real-time confocal microscopy of the cremaster vasculature. This approach allowed the 
separate quantification of leukocyte recruitment in the vessels and in the surrounding tissues. In vehicle-treated 
mice, placement of the TNFα -gel resulted in a near immediate increase in leukocyte accumulation in the ves-
sel wall, which lasted over a prolonged period of time (Fig. 7A). In addition, a marked infiltration of leuko-
cytes into the tissue was observed starting 2 h after TNFα -stimulation, while fewer leukocytes extravasated upon 
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sSiglec-5/C4BP treatment (Fig. 7A). We then quantified the fluorescent signal that was produced under both 
conditions over the 5-h period (integrated fluorescence intensity: IFI for 4 mice/condition and 4 vessels segments/
mouse analyzed), and three values were compared: the IFI of the full microscopic field (Fig. 7B), the IFI of the ves-
sels (Fig. 7C) or the IFI of the surrounding tissue (Fig. 7D). For each of these analyses, the total IFS over the 5-h 
period was significantly reduced for mice treated with sSiglec-5/C4BP compared to vehicle treated mice. These 
data point to a powerful anti-inflammatory potential of sSiglec-5/C4BP.
Figure 3. Immunostaining of PSGL1 and Siglec-5 on human PBMCs. Panel A: Purified human PBMCs 
were stained for PSGL1 and Siglec-5, and the number of positive cells was counted. Presented is the percentage 
positive cells of three independent experiments (mean ± SD; n = 30-60 cells per experiment). Panel B: Confocal 
microscopy image of a representative staining of PBMCs for PSGL1 (green) and Siglec-5 (red). Objective 40x. 
Bar represent 5 micron. Panel C: Confocal microscopy analysis of a representative cell co-expressing PSGL1 
(green) and Siglec-5 (red). Cell stack was reconstituted in orthoview to visualize co-localization of two signals. 
Arrows indicate areas of colocalization. Z-depth is 0.5 μ m, objective 63x. The pixel co-localisation heatmap 
was built using Co-localization Threshold-plugin Fiji Software. Panels D-E: Widefield microscopy images of a 
Duolink-PLA assay for PSGL1 and Siglec-5 incubated in the absence (panel D) or presence (panel E) of primary 
antibodies. Objective 40x. Bars represent 5 micron. For images in panels B-D-E, nuclei were counterstained with 
DAPI (blue).
www.nature.com/scientificreports/
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Figure 4. In vitro perfusion of THP1-cells. Panel A: THP1-cells were incubated with in the absence or 
presence of sialidase prior to perfusion over P-selectin-coated biochips. The number of rolling cells/microscopic 
field were determined and arbitrarily set at 100% for non-desialylated THP1-cells. P-value was determined in a 
two-tailed unpaired t-test. Panel B: THP1-cells were incubated in the absence or presence of soluble Siglec-5/Fc  
(sSg-5/Fc) or Siglec-7/Fc (sSg-7/Fc) prior to perfusion over VCAM1-coated biochips. Plotted is the number 
of adhering cells/microscopic field. Panels C & D: THP1-cells were incubated in the absence or presence of 
www.nature.com/scientificreports/
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Discussion
Siglecs are widely expressed in immune cells of hematopoietic origin, and it seems conceivable that they partic-
ipate in the immune response. Siglec-5 is a well-characterized member of this family, and its expression pattern 
among leukocytes has been reported in detail. Flow cytometric analysis revealed that Siglec-5 is present on neu-
trophils, monocytes, and B-cells, but not on T-cells10,19. This study focused on the potential association between 
Siglec-5 and PSGL1. The latter protein is crucial for the initial recruitment of immune cells to the endothelial 
cells that line the vasculature, and its function relies on the presence of sialic acids covering its glycan structures2. 
The presence of these sialic acids makes PSGL1 a potential ligand for Siglecs. In the present study, we show that 
recombinant variants of PSGL1 and Siglec-5 interact in a calcium-ion and sialic acid-dependent manner. This 
interaction also occurs at the surface of circulating leukocytes that co-express PSGL1 and Siglec-5, given the 
co-localization we observed when analyzing PBMCs. Finally, soluble Siglec-5 interferes with interactions between 
PSGL1 and P-selectin in vitro, and displays strong anti-inflammatory activity in vivo.
When analyzing PBMCs, we observed that about 50% of the cells express both Siglec-5 and PSGL1. This 50% 
corresponds to the potential Siglec-5-positive fraction (monocytes and B-cells) that is present in Ficoll-purified 
PBMCs19,20. Most likely, the Siglec-5 negative population corresponds to T-cells. Two distinct approaches were 
used to determine co-localization of both proteins at the cellular surface: classic immune-staining (Fig. 3C) and 
Duolink-PLA analysis (Fig. 3E). This latter approach generates red fluorescent spots if proteins are located within 
a range of 40 nm, a range compatible with a true co-localization of proteins.
In another set of experiments, we have tried to confirm the interaction between Siglec-5 and PSGL1 at the 
cell-surface via co-immunoprecipitation experiments. However, numerous attempts remained unsuccessful, and 
control experiments using purified proteins revealed that the denaturating conditions needed to free PSGL1 and/
or Siglec-5 from the cellular membrane resulted in dissociation of the PSGL1/Siglec-5 complex. The technical 
limitations therefore prevented us to confirm the interaction of both proteins via this experimental approach.
Despite the technical limitations of the immuno-precipitation, the notion that the ectodomains of PSGL1 and 
Siglec-5 interact was clearly demonstrated when using recombinant purified proteins. These experiments readily 
revealed a dose-dependent, saturable and specific interaction between both proteins (Fig. 2). Control experi-
ments using inhibitory antibodies, EDTA and de-sialylated sPSGL1/Fc confirmed the specificity of the interaction 
(Fig. 2). The observation that de-sialylated sPSGL1/Fc displayed a strongly reduced binding to sSiglec-5/C4BP 
indicates that the interaction relies to a large extent on the sialic acids present on sPSGL1/Fc. This is in agreement 
with the majority of the ligands described for Siglec-5 in particular and the Siglec-family in general. However, it 
is important to mention that not all Siglec-5 ligands are bound in a sialic acid-dependent manner. For instance, 
Group B-streptococcus-protein and coagulation factor VIII have both been reported to interact with Siglec-5 
without the need for sialic acids16,21. Our data do not exclude the possibility that the interaction between PSGL1 
and Siglec-5 is of a mixed nature, involving both sialic acid-dependent and -independent types of interactions.
In the present study, we have not explored the physiological consequences of PSGL1 and Siglec-5 interacting 
at the cell-surface, as this will be part of a separate study. However, it is tempting to speculate on two issues in this 
regard. First, Siglecs, including Siglec-5, are generally known to associate with sialic acid-containing receptors at 
the cell-surface of under resting conditions, while unmasking these receptors upon cell stimulation22. It is possible 
that part of the PSGL1 molecules is associated with Siglec-5 under resting conditions, thereby masking the sialic 
acids of the PSGL1 glycans. Potentially this may prevent excessive premature leukocyte rolling. Upon leukocyte 
stimulation, Siglec-5 would then release PSGL1 to enhance PSGL1-mediated rolling. Second, it has been reported 
that leukocytes may produce soluble Siglec-5 variants11. Further, Biedermann and colleagues have found that 
plasma contains about 75 ng/ml of soluble Siglec-5, and amount that can increased 3–4 fold under pathological 
conditions23. It can not be excluded that increased levels of soluble Siglec-5 may modulate leukocyte rolling under 
these conditions.
Instead of addressing the physiological consequences, we directed our investigations to explore the potential 
of soluble Siglec-5 variants to interfere with PSGL1-dependent leukocyte rolling. In preliminary experiments, 
we used a monomeric soluble Siglec-5 variant, which we have described previously16. Although interacting with 
PSGL1 (data not shown), it did so rather inefficiently. Indeed, glycan-protein interactions are often of relatively 
low affinity and increasing valency via clustering often improves the interaction efficiency24–26. To overcome this 
limitation, two variants were used in this study: a dimeric sSiglec-5/Fc variant and a heptameric sSiglec-5/C4BP 
variant. The heptameric variant was designed based on a report by Libyh and coworkers, who described a scFv 
anti-Rh(D) antibody fused to the 57-amino acid peptide motif of C4BP that mediates heptamerization of the 
protein18. Indeed, upon expression in HEK293-cells, the sSiglec-5/C4BP was efficiently secreted as a single mul-
tivalent protein (Fig. 1). For both sSiglec-5/Fc and sSiglec-5/C4BP, we were able to detect efficient binding to 
PSGL1 in vitro (Fig. 2).
soluble Siglec-5/Fc (sSg-5/Fc; 10 μ g/ml) or Siglec-7/Fc (sSg-7/Fc; 10 μ g/ml) prior to perfusion over E-selectin or 
P-selectin-coated biochips. Plotted is the number of rolling cells/microscopic field. P-values were determined in 
a 1-way ANOVA followed by Dunnett’s test. Panel D: THP1-cells were incubated in the absence or presence of 
sSiglec-5/Fc or anti-PSGL1 antibodies prior to perfusion over P-selectin-coated biochips. Plotted is the number 
of rolling cells/microscopic field, with this number being set as 100% in the absence of sSiglec-5/Fc or anti-
PSGL1 antibodies. P-value was calculated via multiple t-tests according to the Holm-Sidak method. Panels F & 
G: representative image-sequence over a 4-sec period of THP1-cells rolling over P-selectin in the absence (panel 
F) or presence (panel G) of sSiglec-5/Fc. For each image-sequence, six cells have been highlighted to visualize 
their movements over time. For panels A–E: data represent mean ± SD of 3–5 perfusions. For each perfusion, a 
minimum of 3 fields were analyzed. All perfusions were performed at 0.5 dyn/cm2.
www.nature.com/scientificreports/
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Figure 5. In vitro perfusion of primary leukocytes. Panel A: Freshly isolated PBMCs were incubated with in 
the absence or presence of soluble Siglec-5/Fc (sSg-5/Fc; 10 μ g/ml) or Siglec-7/Fc (sSg-7/Fc; 10 μ g/ml) prior 
to perfusion over P-selectin-coated biochips. Perfusion was performed at 2 dyn/cm2. Panel B: Freshly isolated 
PMNs were incubated with in the absence or presence of soluble Siglec-5/Fc (sSg-5/Fc; 10 μ g/ml) or sSiglec-5/
C4BP (sSg-5/C4BP; 10 μ g/ml) prior to perfusion over P-selectin-coated biochips. Perfusion was performed at 
0.5 dyn/cm2. For both panels, the number of rolling cells/microscopic field were determined and arbitrarily 
set at 100% for the control in the absence of Siglecs. Data represent mean ± SD of 3–4 perfusions. For each 
perfusion, a minimum of 3 fields were analyzed. P-values were determined in a 1-way ANOVA followed by 
Dunnett’s test.
Figure 6. Basal leukocyte rolling in vivo. Leukocyte rolling in mesenteric venules (25–35 micron) was 
recorded via video-microscopy for 10 min. Videos were then analyzed for the number of rolling leukocytes 
(panel A) and the number of adhering leukocytes (defined as leukocytes adherent for at least 30 sec; panel B). 
Panel A: Each data point represents the average number of rolling cells/field/min for each mouse. For each 
mouse, 2–3 vessel segments were analyzed. Panel B: Each point represents the cumulative number of adherent 
cells per field over the 10 min observation period. For each mouse, 2 vessel segments were analyzed. Mice 
received either vehicle (open circles) or sSiglec-5/C4BP (0.8 mg/kg via injection in the lateral tail vein; closed 
circles). P-values were determined via a Mann-Whitney test.
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Figure 7. Involvement of sSiglec-5/C4BP in the kinetics of leukocyte recruitment during a sterile 
inflammation in mice. Leukocytes were labeled with fluorescent dye Syto59. Panel A: Representative images 
depicting the course of leukocyte recruitment during a sterile inflammation over time in control mice or mice 
treated with sSiglec-5/C4BP (0.8 mg/kg via injection in the lateral tail vein). Panels B-C-D: The total Integral 
Fluorescent Intensity (IFI) over the 5-h observation period was quantified in control mice or in mice treated 
with Siglec-5. Data represent the IFI of the full microscopic field (panel B), the IFI of the vessels (panel C) or the 
IFI of the surrounding tissue (panel D). Plotted are mean ± SEM from 4 mice per group and 4 vessels per mouse 
(n = 16). P-values were determined using a two-tailed unpaired t-test. Panels E & F: the average rolling velocity 
(panel E) and path duration (panel F) were determined for each vessel segment of each mouse included in the 
study at 4 different time-points during the observation period. Each data point represents the mean of 3–4 cells.
www.nature.com/scientificreports/
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In vitro perfusion studies using human THP1-cells revealed that adhesion to VCAM1 was unaffected by 
sSiglec-5/Fc at a dose of 20 μ g/ml (Fig. 4). The notion that THP1-cells were able to adhere to VCAM1 was per-
haps surprising. However, the shear rates used in these particular experiments were relatively low (0.5 dyn/cm2). 
Moreover, resting THP1-cells express the VCAM1-ligand α 4/β 1, and previous studies have shown that part of 
these α 4/β 1 molecules is in its activated conformation27. We anticipate that the presence of α 4/β 1 in its active 
conformation in combination with the low shear is compatible with the direct adhesion of the THP1-cells to 
VCAM1.
In contrast to the adhesion to VCAM1, rolling on E- and P-selectin was reduced by about 2-fold in the pres-
ence of a similar dose of sSiglec-5/Fc (Fig. 4). This effect seemed specific for Siglec-5, as another member of the 
Siglec-family, Siglec-7, was unable to reduce rolling of THP1-cells on both selectins. Furthermore, sSiglec-5/
Fc-mediated inhibition was dose-dependent and to a large extent similar to that of anti-PSGL1 antibodies (Fig. 4). 
However, at higher doses (50 μ g/ml), sSiglec-5/Fc was more efficient than anti-PSGL1 antibodies in reducing 
THP1-cell rolling. One possibility is that at these concentrations, sSiglec-5/Fc also interferes with the adhesion of 
another P-selectin ligand. A potential candidate is ESL-1, which is expressed on THP1-cells and it binds to 
P-selectin in a glycan-dependent manner28,29. The specificity of sSiglec-5/Fc was not limited to THP1-cells, but 
this soluble protein also reduced rolling of primary leukocytes, both PBMCs and PMNs (Fig. 5). Furthermore, not 
only sSiglec-5/Fc but also its heptameric variant sSiglec-5/C4BP reduced rolling of PMNs in vitro (Fig. 5). Of note, 
a shear stress of 0.5 dyn/cm2 was used in most of the perfusion assays. Although relatively weak compared to the 
shear stress present in post-capillary venules (minimum 2.8 dyn/cm2, with an average of 15 dyn/cm2), 0.5 dyn/cm2 
has been used in other studies concerning the rolling of leukocytes over P-selectin as well30,31. Lawrence and 
coworkers have reported that 0.5 dyn/cm2 represents the actual lower threshold to enhance rolling on P-selectin31. 
Nevertheless, to ensure that sSiglec-5 is also effective at higher shear stress, perfusion experiments using PMBCs 
were performed at 2 dyn/cm2 and also under these conditions rolling was reduced in the presence of sSiglec-5/Fc 
(Fig. 5A). Thus, it seems likely that sSiglec-5/Fc is indeed able to interfere with P-selectin/PSGL1 interactions.
To test its in vivo potential to modulate leukocyte behavior, we initially examined leukocyte rolling under basal 
conditions using a single dose of sSiglec-5/C4BP. In each of the 8 mice that received sSiglec-5/C4BP, the number 
of rolling leukocytes was significantly reduced compared to control mice (Fig. 6). We considered the possibility 
that the effect of sSiglec-5/C4BP would fade out during the examination period. However, similar differences 
between sSiglec-5/C4BP-receiving and control mice were observed in vessels examined at the start and at the end 
of a session, which routinely be separated by 20–40 minutes. It should be noted that the reduced rolling is less pro-
nounced than observed in the in vitro experiments. This could be due to to sSiglec-5/C4BP interacting with other 
sialylated proteins present in the vascular system, and higher doses of sSiglec-5/C4BP could be used to bypass this 
restriction. We also considered the option to use a murine variant of Siglec-5 to this end, as it may provide higher 
specificity for murine ligands. However, human Siglec-5 is not well conserved between species, and no appropri-
ate murine counterpart is available32. Interestingly, we also observed that sSiglec-5/C4BP reduced the number of 
adherent cells (Fig. 6B). PSGL1-dependent rolling over P-selectin is known to induce the Syk-mediated signal-
ing pathway, resulting in activation of LFA-133. This allows LFA-1 to interact with its counter-receptor ICAM-1, 
thereby facilitating firm adhesion of the leukocytes. By blocking PSGL1/P-selectin interactions, sSiglec-5 may 
prevent the activation of LFA-1, and consequently reduce firm adhesion.
The therapeutic potential of sSiglec-5/C4BP was examined in a sterile model of inflammation, in which the 
inflammatory response is triggered by contact with a TNFα -containing gel. Real-time video monitoring over a 
5-h period allowed us to visualize and quantify the full process of leukocyte recruitment and extravasation. The 
exteriorization of cremaster muscle for 5 h may potentially induce inflammation. However, similar to models 
described by others34–36, the cremaster muscle is superfused with thermocontrolled bicarbonate-buffer solution, 
which efficiently suppresses the development of a spontaneous inflammatory response. Indeed, while validating 
this model, no inflammation was observed when the cremaster muscle was exposed to a control gel (agarose/PBS) 
during at least 5 h. Therefore, the inflammatory response observed is selectively due to the presence of TNFα in 
the gel. A second potential point of concern is that blood flow may decrease during the 5-h anesthesia. Although 
not quantified using a blood flow-probe, we could observe blood flow in real-time in the intra-vital setting. We 
did not observe marked differences in blood flow over time in the mice that were included in the data analysis. 
We further chose to use the TNFα /agarose gel rather than to inject TNFα intra-scrotum (i.s.). The main reason to 
do so, is that following i.s. injection, it takes approximately 4 h before the effects of TNFα become visible37,38. By 
applying the TNFα /agarose gel, also the early steps in the inflammatory response can be monitored34.
As compared to vehicle-treated mice, the recruitment of leukocytes was strongly reduced in mice that received 
sSiglec-5/C4BP (Fig. 7), confirming that this protein may interfere with the interaction between PSGL1 and selec-
tins. It was surprising, however, that the effect of sSiglec-5/C4BP persisted over the full 5-h observation period. 
Indeed, deficiency of PSGL1 in mice is associated with a reduced leukocyte recruitment at the early stage (2 h) of 
the inflammatory process, but was only minimally abnormal at the later timepoints6. In contrast, mice that have 
a double deficiency of P- and E-selectin have a severe impairment of leukocyte recruitment over a prolonged 
period of time39,40. The results we obtain with sSiglec-5/C4BP mimic to some extent the combined deficiency 
of P- and E-selectin, with a defect over a prolonged timescale. This suggests that the effects of sSiglec-5/C4BP 
are not limited to P-selectin/PSGL1 interactions, but have a wider impact. This seems compatible with the 
observation that sSiglec-5/Fc also interfered with the rolling of THP1-cells over E-selectin (Fig. 4C). Moreover, 
sSiglec-5/Fc reduced leukocyte rolling on P-selectin to a larger extent compared to anti-PSGL1 antibodies 
(Fig. 4E). Apparently, Siglec-5 is able to interact with a wider range of sialic acid-containing proteins involved in 
the inflammatory response. One possible option in this regard is that sSiglec-5/C4BP interferes with the adhesion 
mediated by the L-selectin axis, given that sL-selectin/Fc displayed efficient binding to sSiglec-5/C4BP in prelim-
inary experiments (Fig. 8). L-selectin is a sialylated protein, and human L-selectin has been described as a ligand 
for E-selectin but not P-selectin41. Interestingly, de-sialysation of L-selectin coincides with a loss of binding to 
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E-selectin41. It is possible therefore that sSiglec-5 binding may interfere with the L-selectin/E-selectin interaction. 
In parallel, sSiglec-5 binding to PSGL1 may prevent the association between PSGL1 and L-selectin as well. In 
contrast, no interaction between sSiglec-5/C4BP and the E-selectin ligand CD44 could be detected.
Irrespective of its precise mode of function, our in vivo data suggest a potent anti-inflammatory action 
by sSiglec-5/C4BP. In recent years, many pathological processes have been described to be dependent on the 
PSGL1/P-selectin pathway, including atherosclerosis42, venous thrombosis43, acute lung injury44, tumor metastasis45, 
and viral infections46,47. It would therefore be of interest to further explore the potential beneficial effects of 
sSiglec-5/C4BP in other pathological conditions.
Material and Methods
Ethics statement. Mice. Housing and experiments of mice were done in accordance with French regula-
tions and the experimental guidelines of the European Community. Animal experiments were approved by the 
local ethical committees of Paris-Sud (Comité d’éthique en experimentation animale n° 26) and Aix-Marseille 
University (Comité d’éthique en experimentation animale n° 14) under numbers 201507271259485 and 
43-17102012, respectively.
Human subjects. Blood was obtained from healthy volunteers via the local blood donor service of the 
University Hospital Bicetre (CHU-Bicetre), approval of which was provided by the Institutional Review Board 
of CHU-Bicetre. All participants gave informed consent for the sampling of blood for scientific purposes per the 
Declaration of Helsinki. Experiments were performed in accordance with the relevant guidelines and regulations.
Proteins. Recombinant soluble Siglec-5 fused to human Fc (sSiglec-5/Fc; cat# 1072-SL, produced in mouse 
myeloma cell-line NS0), human and murine soluble recombinant PSGL1 fused to human Fc (sPSGL1/Fc; cat# 
3345-PS & cat# 7407-PS), recombinant P-selectin (P-selectin; cat# ADP3), VCAM1 (cat# ADP5), soluble recom-
binant human L-selectin fused to human Fc (sL-selectin/Fc; cat# 728-LS), soluble recombinant human CD44 
fused to human F (sCD44/Fc; cat# 3660-CD), polyclonal goat-anti Siglec-5 antibodies (cat# AF1072 & BAF1072), 
and monoclonal mouse anti-Siglec 5 antibody (cat# MAB10721) were all obtained from R&D Systems (Lille, 
France). Monoclonal mouse anti-PSGL1-antibody (cat# 556052) was from BD Pharmigen (Le Pont de Claix, 
France). Monoclonal mouse anti-P-selectin-antibody (cat# 14-0628) was from eBioscience (Paris, France). 
Peroxidase-labeled polyclonal goat-anti-mouse IgG (cat# P0447) was from Dako (Les Ulis, France). Cy3-labeled 
donkey anti-goat-antibodies (cat# ab6949) were from Abcam (Paris, France). AlexaFluor488-labeled donkey 
anti-mouse-antibodies (cat# A-21202) were from ThermoFisher Scientific (Illkirch, France). A fusion protein con-
sisting of the Siglec-5 ectodomain (residues 17–434), residues 541–597 from C4b-binding protein (C4BP) and the 
epitope recognized by antibody HPC4 (designated sSiglec-5/C4BP; Fig. 1) was produced in HEK293-cells and puri-
fied via HPC4-mediated immune-affinity chromatography similarly as described16. Both purified sSiglec-5/C4BP 
and sSiglec-5/Fc were homogeneous as assessed via SDS-PAGE and Coomassie-staining (Fig. 1; see also 
Supplementary Fig. S1). Bovine serum albumin (BSA) and sialidase were from Sigma Aldrich (Saint-Quentin 
Fallavier, France).
Peripheral mononuclear and polymorphonuclear cells. Peripheral Blood Mononuclear Cells 
(PBMCs) and polymorphonuclear cells (PMNs) were freshly isolated from blood obtained from healthy volun-
teers by Ficoll-Plaque density centrifugation. Eventual contaminating erythrocytes were removed by incubation 
with ice-cold lysis buffer (0.155 mM NH4Cl, 7.4 mM KHCO3, 0.1 mM EDTA, pH7.4). Cells were resuspended in 
Hank’s buffered salt solution (Gibco Life Technologies, Saint Aubin, France).
Figure 8. Interaction between sSIglec-5/C4BP and different adhesion proteins. Interaction between sSiglec- 
5/C4BP and sPSGL1/Fc, sL-selectin/Fc and sCD44/Fc was examined using BLI-analysis. sSiglec-5/Fc (10 μ g/ml)  
was immobilized onto amine-reactive biosensors and incubated with a single concentration (10 μ g/ml) of 
sPSGL1/Fc, sL-selectin/Fc and sCD44/Fc. A non-sialylated bacterial protein was used as negative control. A 
representative sensorgram (of three independent measurements) is plotted, showing the response (nm shift) 
versus time.
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Immunostaining. Purified PBMCs were fixed in solution with paraformaldehyde (4%) and dried on glass 
coverslips. Cells were re-hydrated with phosphate-buffered saline (PBS) and further permeabilized via incubation 
with PBS supplemented with 0.05% Tween-20 (PBS-T) and Triton X-100 (0.1%) for 10 min at room temperature. 
Coverslips were blocked with PBS-T containing 5% BSA for 30 min at room temperature. Cells were incubated 
with primary antibodies (polyclonal anti-Siglec-5 and monoclonal anti-PSGL1 antibodies). Bound antibodies 
were probed with Cy3-labeled donkey anti-goat antibodies and AlexaFluor488-labeled donkey anti-mouse anti-
bodies, respectively. Nuclei were counterstained with 1 μ g/ml of 4′ ,6′ -diamino-2-phenylindole (DAPI) and cov-
erslips were mounted in ProlongGold antifade reagent (ThermoFisher Scientific).
For Duolink experiments to detect close proximity between PSGL1 and Siglec-5, a similar double immunos-
taining was performed with the secondary antibodies replaced by secondary PLA-probes from the Duolink kit 
(Sigma Aldrich). The remainder of the protocol was conducted according to the manufacturer’s recommenda-
tions and the orange (555 nm wavelength) detection kit was used. Hybridization between the two PLA plus and 
minus probes leading to fluorescent signal only occurs when the distance between the two antigens is less than 
40 nm.
Microscopic analysis. Widefield microscopy images were acquired on an AxioImager A1 (Carl Zeiss, 
Oberkocher, Germany) and an Eclipse E600 (Nikon, Japan). Confocal microscopy analysis images were acquired 
on a LSM700 (Carl Zeiss) and cell stacks were further deconvolved using Huygens software (Scientific Volume 
Imaging, Hilversum, The Netherlands). Images were analyzed using ImageJ software.
Immunosorbent assays. sPSGL1/Fc (0.25μ g/well) was adsorbed to microtiter wells in 50 mM NaCO3, 
10 mM NaHCO3 (pH9.6) overnight at 4 °C. Unoccupied sites were blocked in Tris-buffered saline with 2.5 mM 
CaCl2, 0.1% Tween-20, and 3% BSA for 2 h at 37 °C. Wells were incubated with various concentrations of sSiglec-5/
C4BP or sSiglec-5/Fc (0–4 μ M). Bound sSiglec-5 was probed using biotin-labeled polyclonal goat anti-Siglec-5 
antibodies and peroxidase-labeled streptavidin and detected via hydrolysis of 3,3′ ,5,5′ -tetramethylbenzidine 
(TMB, Thermofisher Scientific). Optical density (OD) was measured at 450 nm, and OD-values were corrected for 
OD-values obtained for the binding of sSiglec-5 to non-coated wells, which represented < 10% of the OD-values. In 
control experiments, immobilized sPSGL1/Fc was incubated with sSiglec-5 (0.6 μ M) in the presence of polyclonal 
anti-Siglec-5 antibodies (6 μ M) or EDTA (5 mM). In other experiments, immobilized sPSGL1/Fc was incubated 
with P-selectin in the absence or presence of EDTA (5 mM). Bound P-selectin was probed using a monoclonal 
mouse anti-P-selectin antibody and detected using peroxidase-labeled polyclonal goat-anti mouse IgG antibodies.
Biolayer interferometry analysis. In complementary experiments, binding of sPSGL1/Fc to immobilized 
sSiglec-5/C4BP was determined via biolayer-interferometry (BLI)-analysis using Octet-QK equipment. First, 
sPSGL1/Fc (10 μ g/ml) was immobilized onto amine-coupling biosensors and unoccupied sites were quenched 
via incubation with ethanolamine. sPSGL1/Fc-coated biosensors were incubated with various concentrations 
of sSiglec-5/C4BP (0–20 μ g/ml) in octet-buffer (20 mM Hepes, 50 mM NaCl, 2.5 mM CaCl2, pH7.0) and asso-
ciation was monitored for 10 min. Subsequently, sensors were transferred to wells containing octet-buffer for 
10 min in order to allow dissociation of the complex. In another set of experiments, immobilized sPSGL1 was 
pre-incubated with sialidase (0.01 U/ml) before incubation with sSiglec-5/C4BP or P-selectin (both 10 μ g/ml). In 
complementary binding experiments, sSiglec-5/C4BP (10 μ g/ml) was immobilized onto amine-coupling biosen-
sors and incubated with sPSGL1/Fc, sL-selectin/Fc, sCD44/Fc (10 μ g/ml). A non-sialylated bacterial protein was 
used as negative control.
In vitro perfusion assays. In vitro perfusions were performed using a camera-equipped Venaflux- 
Microfluidic platform, allowing real-time video-monitoring. Perfusions were performed using THP1 cells 
(which express both PSGL1 and Siglec-510,48) or primary leukocytes. Perfusions were performed using the 
VenaFlux-perfusion system (Cellix Ltd, Dublin, Ireland) or an in-house developed perfusion system49. Biochips 
were coated with E-selectin, P-selectin or VCAM1 (5 μ g/ml) and exposed to PSGL1-expressing cells, which were 
perfused at a shear of 0.5 dyn/cm2 or 2 dyn/cm2. Where indicated, perfusions were performed in the presence 
of competing proteins (10–50 μ g/ml). Perfusions over BSA- or polyvinylpyrrolidone blocked biochips were 
used as a control, revealing that rolling and adhesion was less than 5% compared to E-selectin, P-selectin or 
VCAM1-coated biochips, respectively. Three images of different fields taken at approximately 100s after initiation 
of the perfusion were used for analysis in all cases.
Basal leukocyte rolling in vivo. Female wild-type C57Bl/6 mice (aged 3–4 weeks) received a single intrave-
nous injection of sSiglec-5/C4BP (0.8 mg/kg) or vehicle in the tail vein. Infusion of sSiglec-5/C4BP had no effect 
on blood counts, as assessed in 12 mice given vehicle (n = 6) or sSiglec-5/C4BP (n = 6). Leukocyte-counts were 
2.8 ± 0.8 × 103 and 2.8 ± 0.5 × 103 cells/μ l, respectively. Also red blood counts (7.5 ± 0.4 × 106 and 7.0 ± 1.1 × 106 
cells/μ l) and platelet counts (920 ± 290 × 103 and 833 ± 189 × 103 platelets/μ l) were similar for both groups. The 
mesenteric vessels of ketamine/xylazine-anesthetized mice were exteriorized (a procedure that takes routinely 
about 15 min) and exposed venules (25–35 micron) were recorded via video-microscopy for 10 min. Per mouse, 
2–3 vessels were monitored. Video-images were then analyzed in a blinded fashion for the number of rolling 
leukocytes and for the number of adhering leukocytes (defined as adhering for > 30 sec).
Preparation of TNFα-containing gel. Agarose (0.4 g) was diluted in 10 ml of distilled water and heated in 
a microwave until agarose dissolution was observed (routinely: 1.5 min at 800 W). A volume of 10 ml 2xPBS was 
warmed and mixed with the agarose-solution to reach a final agarose concentration of 2%. Recombinant murine 
TNFα (Peprotech, Neuilly-sur-Seine, France) was added to 90 μ l of the agarose-solution to a final concentration 
of 0.32 nM. The gel was kept at 4 °C until use.
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In vivo model for TNFα-induced inflammation. Ketamine/xylazin/atropine anesthetized male 
wild-type C57Bl/6 mice (aged 5 weeks) were cannulated in the jugular vein, and the trachea was intubated to 
facilitate spontaneous respiration by the mouse. After the scrotum was incised, the testicle and surrounding cre-
master muscle were exteriorized. Routinely, this procedure lasts about 20 min. Mice were given the fluorescent 
dye Syto59 to label leukocytes, and subsequently sSiglec-5/C4BP was applied (0.8 mg/kg) via a single injection 
through a cannula placed in the jugular vein. Syto59 was used for the staining of neutrophils for two reasons. 
First, to facilitate the quantitative analysis of leukocyte recruitment and extravasation of 4 vessel segments per 
mouse in parallel. Second, by analyzing the fluorescent signal it is possible to distinguish between leukocytes 
present in the blood vessel and extravasated leukocytes. By using brightfield illumination, it would be difficult to 
monitor leukocyte movements in the extravascular space over a 5-h period.
Ten minutes after injection of the protein, a 1-mm3 piece of TNFα -containing 2% agarose gel was deposited 
on a preselected avascular area of the cremaster. Microvessels were observed using an Olympus BX61 WI micro-
scope with a 40× NA water immersion objective. Digital images were captured using a Cooke Sensicam CCD 
camera in 640 × 480-pixel format using an intravital optical system with spinning disk confocal microscopy. All 
experiments were performed using at least 3 mice, and at least 4 venules of 20–40 micron were selected for anal-
ysis in each mouse. The fluorescence intensity, corresponding to the leukocyte recruitment in the vessel or in the 
tissue, was determined with the software Slidebook 5.5 (Intelligent Imaging Innovations, Göttingen, Germany).
Statistics. Single comparisons were performed using two-tailed unpaired t-test or the Mann-Whitney test. 
Multiple comparisons were performed using 1-way ANOVA followed by Dunnett’s test or Tukey’s test. Differences 
were considered significant at p-values below 0.05.
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